Disease Information

General Information of the Disease (ID: DIS00506)

• Name: Esophageal cancer
• ICD: ICD-11: 2B70

Type(s) of Resistant Mechanism of This Disease

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Cisplatin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Pvt1 oncogene (PVT1) [1]

• Metabolic Type: Glutamine metabolism
• Resistant Disease: Esophageal carcinoma [ICD-11: 2B70.Y]
• Resistant Drug: Cisplatin
• Molecule Alteration: Expression; Up-regulation

Differential expression of the molecule in resistant disease

• Classification of Disease: Esophageal cancer [ICD-11: 2B70]
• The Specified Disease: Esophageal carcinoma
• The Studied Tissue: Esophagus
• The Expression Level of Disease Section Compare with the Healthy Individual Tissue: p-value: 6.72E-12; Fold-change: 1.01E+00; Z-score: 7.28E+00
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: ESCA patients; Homo Sapiens
• Experiment for Molecule Alteration: qRT-PCR
• Mechanism Description: We established cisplatin-resistant ESCA cell line (EC109 CDDP Res) and detected that PVT1 and glutamine metabolism were remarkedly elevated in CDDP-resistant esophageal cancer cells. Bioinformatical analysis and luciferase assay illustrated that PVT1 sponged miR-181a-5p to form a ceRNA network, resulting in the downregulation of miR-181a-5p expression in ESCA cells. Glutaminase (GLS), which is a key enzyme in the glutamine metabolism, was identified and validated as a direct target of miR-181-5p in ESCA cells. Inhibiting glutamine metabolism effectively re-sensitized CDDP-resistant cells.

References

• Ref 1: LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis. Nutr Cancer. 2023;75(8):1646-1657.